BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...

Molecular Cancer Research publishes articles featuring novel, basic cancer research discoveries that prioritize broad molecular and cellular processes. Areas of emphasis include cell cycle and ...

BARCELONA, Spain — New phase 3 findings revealed that most patients with newly diagnosed high-risk endometrial cancer did not benefit from receiving ... AstraZeneca, Amgen, BioNTech, Eisai, GSK, ...

ATHENA-COMBO investigators enrolled patients with newly diagnosed stage III/IV ovarian cancer at 294 sites in 24 countries ... Novartis, Corcept, BioNTech, Genmab, DFG, DKH, and Seagen.

Notably, patients benefited from pembrolizumab regardless of whether they achieved a pathologic complete response (pCR), ...

BioNTech stock has climbed 26% over four days as the German biotech rides a round of cancer treatment success from Summit ...

BioNTech (BNTX) stock traded higher on Tuesday after Jefferies upgraded the COVID-19 vaccine maker to Buy, citing the ...

In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...

Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...

Results for Pfizer’s ponsegromab looked promising, while BioNTech and Instil Bio capitalized on momentum surrounding a kind of bispecific antibody.

In a report released today, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on BioNTech SE (BNTX – Research Report), ...

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...